University of Cincinnati Cancer Center researchers in the lab of Jun-Lin Guan have identified a protein that helps prevent metastasis of HER2-positive breast cancer. About 20% of breast cancer patients are HER2-positive, and these cancers tend to be more aggressive than other types.
Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.
